US2020261390A1PendingUtilityA1
Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma
Est. expiryOct 28, 2035(~9.3 yrs left)· nominal 20-yr term from priority
A61K 31/05A61K 47/542A61P 3/00A61P 9/00A61K 31/198
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least one week.
Claims
exact text as granted — not AI-modified1 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
providing to the mammal in need thereof with a composition of 10 mg to 5000 mg daily of trans-resveratrol and arginine for at least one week.
2 . The method according to claim 1 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition.
3 . The method according to claim 1 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the conjugate.
4 . The method according to claim 1 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal.
5 . The method according to claim 1 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal.
6 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
providing a mammal in need thereof with a composition of 10 mg to 5000 mg of a trans-resveratrol and arginine for at least two weeks.
7 . The method according to claim 6 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition.
8 . The method according to claim 6 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the composition.
9 . The method according to claim 6 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal.
10 . The method according to claim 6 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal.
11 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
administering to a mammal in need thereof a composition of 10 mg to 5000 mg of a trans-resveratrol and arginine for at least one week, wherein the trans-resveratrol and arginine composition increases amounts of resveratrol in plasma levels of the mammal within at least 30 minutes of providing trans-resveratrol and arginine composition to the mammal.
12 . The method according to claim 11 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition.
13 . The method according to claim 11 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the composition to the mammal.
14 . The method according to claim 11 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal.
15 . The method according to claim 11 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal.Join the waitlist — get patent alerts
Track US2020261390A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.